Five (62.5%) of eight patients with PTC with lymph node metastasis expressed a BRAF V600E mutation, while seven (77.78%) of nine PTC without lymph node metastasis harbored the mutation (Table 3). Here, BRAF is linked to metastatic malignant neoplasm in the lymph nodes.